Breast cancer mortality after a diagnosis of ductal carcinoma in situ

JAMA Oncology

Volumn 1, Issue 7, 2015, Pages 888-896

  Narod, Steven A ^a,b   Iqbal, Javaid ^a   Giannakeas, Vasily ^a,b   Sopik, Victoria ^a   Sun, Ping ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; AGED; BREAST NEOPLASMS; CANCER REGISTRY; CANCER STAGING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CAUSE OF DEATH; DISEASE COURSE; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SEGMENTAL MASTECTOMY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84965092320     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2510     Document Type: Article

References (32)

1. Ernster VL, Ballard-Barbash R, BarlowWE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94(20): 1546-1554.
2. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008; 100(22): 1643-1648.
3. Ernster VL, Barclay J, Kerlikowske K,Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med. 2000; 160 (7): 953-958.
4. Romero L, Klein L, YeW, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2004; 188(4): 371-376.
5. Donker M, Litière S,Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013; 31(32): 4054-4059.
6. Wärnberg F, Bergh J, Zack M, Holmberg L. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: A population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev. 2001; 10(5): 495-499.
7. Wärnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014; 32 (32): 3613-3618.
8. US Census Bureau. 2007-2011 American Community Survey. Table B19013: Median household income in the past 12 months (in 2011 inflation-adjusted dollars). American Community Survey 5-year estimates. http: //factfinder.census .gov/faces/nav/jsf/pages/index.xhtml. Accessed August 10, 2015.
9. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015; 313(2): 165-173.
10. Correa C, McGale P, Taylor C, et al; EarlyBreast Cancer Trialists' Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010; 2010(41): 162-177.
11. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996; 275(12): 913-918.
12. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds. WHO Classification of Tumours of the Breast. 4th ed. Lyon: IARC; 2012.
13. Habel LA, Daling JR, Newcomb PA, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1998; 7 (8): 689-696.
14. SandersME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015; 28(5): 662-669.
15. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011; 103(6): 478-488.
16. Roses RE, Arun BK, Lari SA, et al. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011; 18(10): 2873-2878.
17. Collins LC, Achacoso N, Haque R, et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013; 139(2): 453-460.
18. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001; 19(8): 2263-2271.
19. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Five-year observations concerning lobular carcinoma in situ. Cancer. 1996; 78(7): 1403-1416.
20. Rakovitch E,Mihai A, Pignol JP, et al. Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ? Breast Cancer Res Treat. 2004; 87(3): 265-272.
21. SilversteinMJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999; 340(19): 1455-1461.
22. Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the US SEER database. Breast Cancer Res Treat. 2005; 89(1): 47-54.
23. Schairer C,Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004; 96(17): 1311-1321.
24. Narod SA. Breast cancer in young women. Nat Rev Clin Oncol. 2012; 9(8): 460-470.
25. Copson E, Eccles B, Maishman T, et al; POSH Study Steering Group. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: The POSH study. J Natl Cancer Inst. 2013; 105(13): 978-988.
26. McGale P, Taylor C, Correa C, et al; EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935): 2127-2135.
27. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16): 1233-1241.
28. Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys. 2005; 63(5): 1514-1521.
29. Punglia RS, Schnitt SJ,Weeks JC. Treatment of ductal carcinoma in situ after excision: Would a prophylactic paradigm be more appropriate? J Natl Cancer Inst. 2013; 105(20): 1527-1533.
30. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013; 173(19): 1830-1831.
31. McCormick B, Winter K, Hudis C, et al. RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015; 33(7): 709-715.
32. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013; 105(10): 701-710.